Low molecular weight heparin vs vitamin K antagonist (VKA)
Thrombocytopenia (up to 3 months)n · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) probably leads to higher thrombocytopenia (up to 3 months)n compared with vitamin K antagonist (VKA) (moderate certainty).
1 finding from 1 review
- Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes onlyRR 1.69 [1.2, 2.39]2 studies · 327 participantsModerate